Thor Medical ASA - Asset Resilience Ratio
Thor Medical ASA (TRMED) has an Asset Resilience Ratio of 25.48% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Thor Medical ASA working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Thor Medical ASA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see TRMED total asset value.
Liquid Assets Composition Over Time
This chart breaks down Thor Medical ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read how much debt does Thor Medical ASA carry for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr180.56 Million | 25.48% |
| Short-term Investments | Nkr0.00 | 0% |
| Total Liquid Assets | Nkr180.56 Million | 25.48% |
Asset Resilience Insights
- Very High Liquidity: Thor Medical ASA maintains exceptional liquid asset reserves at 25.48% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Thor Medical ASA Industry Peers by Asset Resilience Ratio
Compare Thor Medical ASA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Thor Medical ASA (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Thor Medical ASA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | Nkr1.00K ≈ $105.23 |
Nkr414.40 Million ≈ $43.61 Million |
-12.77pp |
| 2023-12-31 | 12.77% | Nkr42.25 Million ≈ $4.45 Million |
Nkr330.83 Million ≈ $34.81 Million |
-77.26pp |
| 2022-12-31 | 90.03% | Nkr98.72 Million ≈ $10.39 Million |
Nkr109.64 Million ≈ $11.54 Million |
-3.57pp |
| 2021-12-31 | 93.61% | Nkr277.71 Million ≈ $29.22 Million |
Nkr296.67 Million ≈ $31.22 Million |
+0.17pp |
| 2020-12-31 | 93.44% | Nkr293.98 Million ≈ $30.93 Million |
Nkr314.61 Million ≈ $33.11 Million |
-- |
About Thor Medical ASA
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It offers thorium-228, as well as radium-224 and lead-212 to radiopharmaceutical customers. The company was incorporated in 2009 and is headquartered in Oslo, Norway.